Member Info for crumbs

I don't know much about this but isn't it the case that Redx is not being bought out but 'merging' with NASDAQ-listed Jounce I suppose as a way of getting it onto the NASDAQ.... I wonder what Redmile's hand in that was? Again I know virtually nothing about it lol but I do feel Redmile's plan here is to one day with enough high profile from data and deals to take Scancell onto the NASDAQ.... hopefully not by a merger... unless its with Pfizer or something !!....Anyway Redx's poor data RNS could of been worse it could have said 'encouraging' :)))

I'd say yet more evidence of 'it's working' :))

Of course, absolutely any benefit to patients especially with such late-stage progressive disease is very good news....As I've said before this trial will bring answers and raise questions.... and scancell team science will science the heck out of it! One endpoint will be tumor-infiltrating lymphocytes -proving that cytotoxic CD4 t cells have migrated to and infiltrated the tumor where they have recognised tumor-specific antigens and elicited a direct and indirect cytotoxic activity.....That will mean the science of moditope is good science and that this is a whole new class of immunotherapy worth investing zillions in :)

Tumour vanishing is what moditope does once that cascade effect kicks in... that is just the science of it

Of 14 so far assessed patients which include the 3 patients of Cohort 1 (low dose of vimentins only) 8 patients are responding in what looks to be a beneficial way....That is over half % with the trial so far biased towards the target of late stage Ovarian (a very tough one to treat).... Sure we are not seeing that cascade effect just yet-tumors vanishing(a complete response) but I reckon we will... As Lindy once said there will be some patients who have really good autophagy and respond to all 3 peptides of the modi 1 vaccine

Berm there is a patient from cohort 1 that has had a positive response which is remarkable given that is from a safety dose
from the interims:
'one ovarian patient in Cohort 1 and one in Cohort 2 have stable disease.'

Don't know if this article has been posted here but since its goodbye to electroporation and old mates Ichor (enjoy the payout)) The future currently for ImmunoBody lies with Pharmajet delivery and all the advantages of that... not least the attractiveness to a potential first loooong overdue deal on that platform...

https://www.businesswire.com/news/home/20230223005078/en/Review-Highlights-Growing-Evidence-That-PharmaJet%E2%80%99s-Precision-Delivery-Devices-Improve-Nucleic-Acid-Vaccine-Performance

I don't think you should read anything into that 3 trials it'll just be the standard blurb that hasn't been updated... even if a partner were found there is no Covidity trial being currently run..... Always good to see the team growing in strength though... I expect it is more to do with the expansion of Modify and SCIB1 combo trials...

Are we getting the skunkworks?

Thing is that there is a vaccine immune response CD4 Cells are being triggered and it does look like they are going after the correct target and not self.... The question for me is although that part is all positive we know that moditope working working would show complete responses ... we haven't seen that -yet ... patient 1 you might have expected after showing such a good tumor response would have gone complete response because well that is what moditope is supposed to do..... the cascade effect of under T cell attack cancer becoming more and more stressed causing the CD4s to go even more cytotoxic-causing a complete response so do the T cells become exhausted is the response too weak can that be fixed is there some way cancer can evade or switch off the response once it has been triggered or will complete response indeed be the result it just takes a while longer, we dunno its a trial ...Still early days and of course these are hard stage hard targets but moditope needs tumors to do its stuff.... Of course, absolutely any benefit to patients is worthy and the immune response ought to be sustained even after dosing is completed ....the picture will become clearer and there will be answers to the raised questions also this is team scancell science we know they will get the best out this platform..... so long as the money comes in :)

As a trial, it of course answers questions and raises other ones, patterns will emerge at the moment the one clear pattern is the universal DTH response....And without it well..the trial would probably be coming to an end already....That it is so far seen in all dosed patients means we will get a very clear picture of modi 1's potential and limits in its cohorts and chosen trial targets and of the utility of the moditope platform

Those successfully modi 1 vaccine-triggered CD4 T Cells (evidenced by the DTHs) must be going somewhere and doing something ....

One interesting approach is
under development by the Oxford
based start-up Scancell. The fi rm’s
Moditope platform aims to enlist
CD4+ T cells, rather than CD8+ T
cells. The former are sometimes
called “helper” cells that coordinate
activity by cytotoxic CD8+ T cells,
which are those that directly
challenge pathogens in the body.
Lindy Durrant, chief executive of
Scancell, explains that the idea is to
prime the CD4+ T cells in such a way
that, when they enter tumours, they
provoke infl ammation in the cells,
which would otherwise be absent.
This should allow the CD4+ T cells to
become cytotoxic themselves, detect
the target peptides on the tumour
cells, and then destroy them—rather
like ripping the invisibility cloak off
an intruder.
“If you can really get good
infl ammation and good, targeted
T cells in these tumours, you can just
make [the tumours] disappear,” says
Durrant. Referring to unpublished
data from an ongoing trial, she
mentions that one patient has
demonstrated a 36% reduction
in tumour size after just two
immunisations (of a total of fi ve).
Biopsies from this patient are
due to be analysed to confi rm the
presence and activity of immune
cells. Durrant says, “I can’t really
believe that result yet; we need to get
more.” Around 140 patients will take
part in the phase 1/2 trial, due to
complete in 2026.
https://www.bmj.com/bmj/section-pdf/1079078?path=/bmj/380/8370/This_Week.full.pdf
page 15

Yeah, I guess you can think of it like this ...treatments are mostly about you taking a drug and it either works or does not or it works for bit and then stops working... whereas with the kind of immune response that scancells vaccines when they work induce you basically should benefit for life .... SCIB1 trial patients still benefiting.... So like you say though tumor shrinkage is of course the thing to see it's not the whole story... so long as those T cells are actively targeting cancer cells where ever they are not just in visible tumors then the vaccine is doing its job

TBH and I don't think I'm alone I'd be surprised if Covidity alone finds a partner, I think it would be more likely the whole ImmunoBody platform was wholely partnered or partnered separately for targeting viral diseases and or for targetting cancers or possibly sold as a whole with a license for Avidimab use included...

The next news will be Sanofi partner Covidity and Seagen doing a licensing deal on AvidiMab... obviously! :))

'The aim of my PhD project was to generate novel anti-glycan monoclonal antibodies against tumours. During my PhD I had generated three mAbs, of which two of them had been granted a patent. We collaborated with university research groups and companies such as Seattle Genetics, OMT and Invivogen to look for the potential clinical usage of our mAbs. For e.g., ADC and generation of human antibody. These three mAbs are potent direct cancer cell killers. In addition to ADCC and CDC, the antibodies also cause direct cytotoxicity to cancer cells.'

You'll find a connection with Seagen (once Seattle Genetics) GenMab and quite a few interesting others with their use of Open monoclonal technology INC tech or MaB development ....And who was an early adopter of this tech.... yeah our Lindy ;)
Seattle Genetics link with with Clycan Mabs goes way back to Notts Uni work

https://www.businesswire.com/news/home/20150318005417/en/Open-Monoclonal-Technology-Grants-OmniAb-License-to-The-University-of-Nottingham

There is a stage 4... T cell Memory, which is quite beautiful -vaccinated mice that successfully dissolved their cancer tumors and then rejected further attempts to re-establish cancer tumors

'Hi Lindy

How is the DTH manifesting itself is like an allergic reaction around the injection site ... which is measurable ?

just trying to quantify as you can use DTH as a test as well at a future date ..

reply

Yes DTH is measurable.
kind Regards,
lindy'